Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

Clinical trial NCT07703228 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07703228
Sponsor: Nanfang Hospital, Southern Medical University
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IIIB~IV Second-line Therapy Metastases

Start date: 2025-08-13
Primary completion: 2027-09-30
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.